Detect Bladder Cancer by UroVysion®

Fluorescence In-Situ Hybridization technology to detect chromosomal and gene changes unique to bladder cancer

Many bladder cancers are diagnosed at an early stage when the disease is highly treatable. However, even early stage bladder cancers have a high risk of recurrence, requiring that survivors undergo regular follow-up tests after treatment. We offer UroVysion™ in order to accurately detect and monitor bladder cancers.


Pathologist-Guided Interpretations

Biomarkers of Interest detected by IHC and interpreted

Prostate cancer is the most common cancer among men and the second leading cause of death for men in the United States. Our expert suite of services can provide diagnosis as well as guidance for treatment decisions. From early detection to informed decision making, our Molecular Center of Excellence supports the physician and patient.

Learn more about our UroVysion™ and Prostate testing services.

How To Order
Test Directory

Sample Reports 

UroVicon1-e1439838330182 UroVicon2-e1439838318248 KSAicon-e1439838277548